Key points from article :
$72,000 raised for high-throughput screening of a library of diverse drugs to find treatments for ‘ALT’ cancers.
ALT cancers rely on Alternative Lengthening of Telomeres.
Telomere shortening acts as a biological mechanism for limiting cellular life span.
Most cancer cells bypass this failsafe by synthesizing new telomeres using the enzyme telomerase.
There are currently no ALT-targeted anti-cancer therapeutics.
The study was published in the PubMed Central.
